drugset / Trial / NCT05861102
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).
Timeline
- Start
- 2023-07-20
- Primary completion
- 2025-06-09
- Completion
- 2025-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 100 mg | Oral |